Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Zrt.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-4847-5700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$661.91 million
Profitability
Miscellaneous
Employees1,490
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions
What is Taro Pharmaceutical Industries' stock symbol?
Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."
How often does Taro Pharmaceutical Industries pay dividends? What is the dividend yield for Taro Pharmaceutical Industries?
Taro Pharmaceutical Industries announced a dividend on Monday, November 5th. Stockholders of record on Tuesday, December 11th will be paid a dividend of $12.81 per share on Friday, December 28th. The ex-dividend date of this dividend is Monday, December 10th. View Taro Pharmaceutical Industries' Dividend History.
How were Taro Pharmaceutical Industries' earnings last quarter?
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced its earnings results on Wednesday, May, 22nd. The company reported $1.52 earnings per share for the quarter, missing analysts' consensus estimates of $2.26 by $0.74. The firm earned $179.92 million during the quarter, compared to analyst estimates of $189.90 million. Taro Pharmaceutical Industries had a return on equity of 14.27% and a net margin of 46.55%. View Taro Pharmaceutical Industries' Earnings History.
When is Taro Pharmaceutical Industries' next earnings date?
What price target have analysts set for TARO?
1 brokers have issued 12 month price objectives for Taro Pharmaceutical Industries' stock. Their predictions range from $115.00 to $115.00. On average, they anticipate Taro Pharmaceutical Industries' stock price to reach $115.00 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price. View Analyst Price Targets for Taro Pharmaceutical Industries.
What is the consensus analysts' recommendation for Taro Pharmaceutical Industries?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Taro Pharmaceutical Industries.
What are Wall Street analysts saying about Taro Pharmaceutical Industries stock?
Here are some recent quotes from research analysts about Taro Pharmaceutical Industries stock:
- 1. According to Zacks Investment Research, "Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals used in their production. Products are sold through wholesalers, generic drug distributors, drug store chains, mass merchandisers, HMOs, food stores, pharmacies and hospitals. " (4/3/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We ascribe a price objective of $115 per share, based on a forward EPS multiple of 15.5x applied to our current fiscal 2019 EPS forecast of $7.40 per share." (12/10/2018)
Has Taro Pharmaceutical Industries been receiving favorable news coverage?
Press coverage about TARO stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Taro Pharmaceutical Industries earned a daily sentiment score of 1.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Taro Pharmaceutical Industries' key competitors?
Some companies that are related to Taro Pharmaceutical Industries include BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GNMSF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO) and Marina Biotech (MRNA).
What other stocks do shareholders of Taro Pharmaceutical Industries own?
Who are Taro Pharmaceutical Industries' key executives?
Taro Pharmaceutical Industries' management team includes the folowing people:
- Mr. Uday V. Baldota, CEO & Director (Age 49)
- Mr. Mariano Balaguer, CFO, Chief Accounting Officer & VP (Age 46)
- Mr. Itamar Karsenti, VP & Head of Global Operations (Age 47)
- Mr. Itzik Baruch, VP of Technical Services (Age 56)
- Dr. Roman Kaplan Ph.D., VP of Scientific and Technical Compliance Mang. (Age 72)
Who are Taro Pharmaceutical Industries' major shareholders?
Taro Pharmaceutical Industries' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (1.53%), Renaissance Technologies LLC (1.08%), Acadian Asset Management LLC (0.91%), Dimensional Fund Advisors LP (0.80%), AJO LP (0.55%) and Freestone Capital Holdings LLC (0.33%).
Which institutional investors are selling Taro Pharmaceutical Industries stock?
TARO stock was sold by a variety of institutional investors in the last quarter, including Fort L.P., FMR LLC, Goldman Sachs Group Inc., Actinver Wealth Management Inc., JPMorgan Chase & Co., Northern Trust Corp, Empirical Finance LLC and BlueMountain Capital Management LLC.
Which institutional investors are buying Taro Pharmaceutical Industries stock?
TARO stock was acquired by a variety of institutional investors in the last quarter, including Hotchkis & Wiley Capital Management LLC, Hotchkis & Wiley Capital Management LLC, Acadian Asset Management LLC, Renaissance Technologies LLC, AJO LP, First Manhattan Co., Freestone Capital Holdings LLC and Caisse DE Depot ET Placement DU Quebec.
How do I buy shares of Taro Pharmaceutical Industries?
Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Taro Pharmaceutical Industries' stock price today?
One share of TARO stock can currently be purchased for approximately $94.65.
How big of a company is Taro Pharmaceutical Industries?
Taro Pharmaceutical Industries has a market capitalization of $3.73 billion and generates $661.91 million in revenue each year. The company earns $211.15 million in net income (profit) each year or $6.18 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,490 workers across the globe.
What is Taro Pharmaceutical Industries' official website?
How can I contact Taro Pharmaceutical Industries?
Taro Pharmaceutical Industries' mailing address is 14 HAKTOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]
MarketBeat Community Rating for Taro Pharmaceutical Industries (NYSE TARO)
MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TARO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TARO will underperform the S&P 500 over the long term. You may vote once every thirty days.
